UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2006
OR
| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 0-32405
SEATTLE GENETICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 91-1874389 | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
21823 30th Drive SE
Bothell, Washington 98021
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code): (425) 527-4000
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):
Large Accelerated Filer ¨ Accelerated Filer x Non-accelerated filer ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ¨ NO x
As of November 3, 2006, there were 51,026,815 shares of the registrant’s common stock outstanding.
1
Seattle Genetics, Inc.
For the quarter ended September 30, 2006
| Page | ||||
| PART I. FINANCIAL INFORMATION (Unaudited) |
||||
| Item 1. |
3 | |||
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 | ||||
| Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
12 | ||
| Item 3. |
18 | |||
| Item 4. |
18 | |||
| PART II. OTHER INFORMATION |
||||
| Item 1A |
18 | |||
| Item 6. |
19 | |||
| 20 | ||||
| 21 | ||||
2
PART I. FINANCIAL INFORMATION
| Item 1. | Financial Statements |
Condensed Balance Sheets
(Unaudited)
(In thousands)
| September 30, 2006 |
December 31, 2005 |
|||||||
| Assets |
||||||||
| Current assets |
||||||||
| Cash and cash equivalents |
$ | 27,911 | $ | 11,156 | ||||
| Short-term investments |
58,964 | 31,315 | ||||||
| Interest receivable |
715 | 678 | ||||||
| Accounts receivable |
734 | 683 | ||||||
| Prepaid expenses and other |
1,083 | 314 | ||||||
| Total current assets |
89,407 | 44,146 | ||||||
| Property and equipment, net |
7,864 | 8,532 | ||||||
| Restricted investments |
494 | 605 | ||||||
| Long-term investments |
9,496 | 36,736 | ||||||
| Total assets |
$ | 107,261 | $ | 90,019 | ||||
| Liabilities and Stockholders’ Equity |
||||||||
| Current liabilities |
||||||||
| Accounts payable and accrued liabilities |
$ | 5,197 | $ | 5,045 | ||||
| Current portion of deferred revenue |
4,156 | 6,053 | ||||||
| Total current liabilities |
9,353 | 11,098 | ||||||
| Long-term liabilities |
||||||||
| Deferred rent |
517 | 513 | ||||||
| Deferred revenue, less current portion |
648 | 2,950 | ||||||
| Total long-term liabilities |
1,165 | 3,463 | ||||||
| Commitments and contingencies |
||||||||
| Stockholders’ equity |
||||||||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: |
||||||||
| Series A convertible preferred stock, 1,500,000 shares issued and outstanding at September 30, 2006 and at December 31, 2005 |
2 | 2 | ||||||
| Common stock, $0.001 par value, 100,000,000 shares authorized; 51,014,328 shares issued and outstanding at September 30, 2006 and 42,379,895 issued and outstanding at December 31, 2005 |
51 | 42 | ||||||
| Additional paid-in capital |
266,274 | 219,159 | ||||||
| Accumulated other comprehensive loss |
(15 | ) | (171 | ) | ||||
| Accumulated deficit |
(169,569 | ) | (143,574 | ) | ||||
| Total stockholders’ equity |
96,743 | 75,458 | ||||||
| Total liabilities and stockholders’ equity |
$ | 107,261 | $ | 90,019 | ||||
The accompanying notes are an integral part of these financial statements.
3
Condensed Statements of Operations
(Unaudited)
(In thousands, except per share amounts)
| Three months ended September 30, |
Nine months ended September 30, |
|||||||||||||||
| 2006 | 2005 | 2006 | 2005 | |||||||||||||
| Revenues |
||||||||||||||||
| Collaboration and license agreements |
$ | 2,441 | $ | 2,632 | $ | 7,422 | $ | 7,438 | ||||||||
| Operating expenses |
||||||||||||||||
| Research and development |
9,797 | 7,806 | 29,055 | 26,146 | ||||||||||||
| General and administrative |
2,619 | 1,664 | 7,328 | 5,366 | ||||||||||||
| Total operating expenses |
12,416 | 9,470 | 36,383 | 31,512 | ||||||||||||
| Loss from operations |
(9,975 | ) | (6,838 | ) | (28,961 | ) | (24,074 | ) | ||||||||
| Investment income, net |
1,326 | 667 | 2,966 | 1,990 | ||||||||||||
| Net loss |
$ | (8,649 | ) | $ | (6,171 | ) | $ | (25,995 | ) | $ | (22,084 | ) | ||||
| Net loss per share – basic and diluted |
$ | (0.17 | ) | $ | (0.15 | ) | $ | (0.54 | ) | $ | (0.52 | ) | ||||
| Shares used in computation of net loss per share - basic and diluted |
50,997 | 42,317 | 47,862 | 42,191 | ||||||||||||
The accompanying notes are an integral part of these financial statements.
4
Condensed Statements of Cash Flows
(Unaudited)
(In thousands)
| Nine months ended September 30, |
||||||||
| 2006 | 2005 | |||||||
| Operating activities |
||||||||
| Net loss |
$ | (25,995 | ) | $ | (22,084 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities |
||||||||
| Stock compensation expense |
3,244 | 10 | ||||||
| Depreciation and amortization |
1,802 | 1,733 | ||||||
| Realized loss and amortization on investments |
334 | 951 | ||||||
| Deferred rent |
4 | 35 | ||||||
| Changes in operating assets and liabilities |
||||||||
| Interest receivable |
(37 | ) | 70 | |||||
| Accounts receivable |
(51 | ) | 605 | |||||
| Prepaid expenses and other |
(745 | ) | (54 | ) | ||||
| Accounts payable and accrued liabilities |
152 | (34 | ) | |||||
| Deferred revenue |
(4,199 | ) | 432 | |||||
| Net cash used in operating activities |
(25,491 | ) | (18,336 | ) | ||||
| Investing activities |
||||||||
| Purchases of investments |
(79,509 | ) | (34,529 | ) | ||||
| Proceeds from sales and maturities of investments |
79,033 | 54,193 | ||||||
| Purchases of property and equipment |
(1,158 | ) | (1,190 | ) | ||||
| Net cash (used in) provided by investing activities |
(1,634 | ) | 18,474 | |||||
| Financing activities |
||||||||
| Net proceeds from issuance of common stock |
43,146 | — | ||||||
| Proceeds from exercise of stock options and employee stock purchase plan |
734 | 1,123 | ||||||
| Net cash provided by financing activities |
43,880 | 1,123 | ||||||
| Net increase in cash and cash equivalents |
16,755 | 1,261 | ||||||
| Cash and cash equivalents, at beginning of period |
11,156 | 9,645 | ||||||
| Cash and cash equivalents, at end of period |
$ | 27,911 | $ | 10,906 | ||||
The accompanying notes are an integral part of these financial statements.
5
Notes to Condensed Financial Statements
(Unaudited)
1. Basis of presentation
The accompanying unaudited condensed interim financial statements of Seattle Genetics, Inc. (“Seattle Genetics” or the “Company”) have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and generally accepted accounting principles for unaudited condensed interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. These financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and results of its operations, as of and for the periods presented. Management has determined that the Company operates in one segment. Unless indicated otherwise, all amounts presented in financial tables are presented in thousands, except for per share amounts.
These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2005 as filed with the SEC.
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of the Company’s operations for the three month and nine month periods ended September 30, 2006 are not necessarily indicative of the results to be expected for a full year.
2. Recent Accounting Pronouncements
In July 2006, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statement No. 109 (“FIN 48”), which provides criteria for the recognition, measurement, presentation and disclosure of uncertain income tax positions. A tax benefit from an uncertain income tax position may be recognized only if it is “more likely than not” that the position is sustainable based on its technical merits. The provisions of FIN 48 are effective for fiscal years beginning after December 15, 2006. The Company is currently evaluating the impact that FIN 48 will have on its financial condition or results of operations; however, the Company does not believe that the adoption of FIN 48 will have a material impact given its net operating losses.
In September 2006, the Securities and Exchange Commission (SEC) issued Staff Accounting Bulletin No. 108 (SAB 108). SAB 108 allows for the adjustment of the cumulative effect of prior year immaterial errors in assets and liabilities as of the beginning of the fiscal year with an offsetting adjustment to the opening balance of retained earnings. There have been two common approaches used to quantify such errors. Under one approach, the error is quantified as the amount by which the current year income statement is misstated. The other approach quantifies the error as the cumulative amount by which the current year balance sheet is misstated. The Company does not expect the adoption of SAB 108 to have a material impact on its financial statements.
3. Stock compensation expense
Prior to January 1, 2006, the Company accounted for share-based payments under the recognition and measurement provisions of APB Opinion No. 25, Accounting for Stock Issued to Employees (“APB 25”), and related Interpretations, as permitted by FASB Statement No. 123, Accounting for Stock-Based Compensation (“FAS 123”). In accordance with APB 25, no compensation cost was recognized for options granted to employees that had an exercise price equal to or greater than the market value of the underlying common stock on the date of grant.
On January 1, 2006, the Company adopted the fair value recognition provisions of Financial Accounting Standards Board (“FASB”) Statement No. 123(R), Share-Based Payment (“FAS 123R”) using the modified prospective method. Under this transition method, compensation cost recognized for the period ended September 30, 2006 includes: (a) compensation cost related to stock options granted prior to, but not yet vested as of January 1, 2006, based on the grant-date fair value estimated in accordance with the original provisions of FAS 123; (b) compensation cost related to stock options granted subsequent to January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of FAS 123R; and (c) compensation costs related to the Company’s employee stock purchase plan. In each case, expense recorded in periods subsequent to January 1, 2006 reflects the service cost of the underlying share-based payment attributable to the period. In accordance with the modified prospective method, the results for the prior periods have not been restated.
6
The Company uses the straight-line attribution method for recognizing compensation expense under FAS 123R. Previously, under the disclosure-only provisions of FAS 123, the Company used the accelerated method of expense recognition pursuant to FASB Interpretation No. 28, Accounting for Stock Appreciation Rights and Other Variable Stock Option or Award Plans (“FIN 28”). For all unvested options outstanding as of January 1, 2006, the previously measured but unrecognized compensation expense, based on the fair value at the original grant date, will be recognized on an accelerated basis over the remaining vesting period. For share-based payments granted subsequent to January 1, 2006, compensation expense, based on the fair value on the date of grant, will be recognized on a straight-line basis over the vesting period. Compensation expense is recognized on awards ultimately expected to vest and reduced for forfeitures that are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
The Company accounts for options issued to non-employees under FAS 123 and EITF Issue No. 96-18, “Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services.” As such, the value of such options is periodically re-measured and adjusted as necessary during their vesting terms.
Description of share-based payment plans
The Company has a 1998 Stock Option Plan (Option Plan) and a 2000 Directors’ Stock Option Plan (Directors’ Plan) as share-based payment plans for employees, members of its scientific advisory board and non-employee members of its board of directors. Stock options granted under these plans generally vest over a four-year period with 25% vested on the anniversary date of the grant followed thereafter by monthly vesting. Annual stock option grants to members of the board of directors vest in full after one year. The options generally expire ten years from the date of grant. At September 30, 2006, approximately 10.8 million shares were authorized for grant under these plans, including approximately 1.9 million shares which were available for future grant under such plans.
The Company also has a 2000 Employee Stock Purchase Plan (Stock Purchase Plan). Under the terms of the Stock Purchase Plan, eligible employees may purchase shares of the Company’s common stock every six months over an offering period with a maximum duration of two years. Under the Stock Purchase Plan, shares of common stock are purchased at 85% of the lower of the fair market value of the stock on (i) the first day of the applicable offering period or (ii) the last day of the then current six month purchase period. A total of 96,617 shares were sold to employees during the nine months ended September 30, 2006 and 97,342 shares in the comparable period in 2005. At September 30, 2006, approximately 736,000 shares of common stock were reserved for issuance under the Stock Purchase Plan.
Impact of the adoption of FAS 123R
The impact on the Company’s results of operations of recording share-based payment awards to employees and directors including employee stock options pursuant to the Company’s Option Plan and Directors’ Plan and employee stock purchases pursuant to the Company Stock Purchase Plan for each respective period is as follows (in thousands):
| Three Months Ended September 30, 2006 |
Nine months Ended September 30, 2006 | |||||
| Research and development |
$ | 856 | $ | 1,997 | ||
| General and administrative |
428 | 1,185 | ||||
| Total |
$ | 1,284 | $ | 3,182 | ||
Due to the adoption of FAS 123R, the Company’s basic and diluted net loss increased by $0.03 per share for the three months ended September 30, 2006 and increased by $0.07 per share for the nine months ended September 30, 2006. The Company granted options to purchase a total of 15,000 shares to certain members of its scientific advisory board during the nine months ended September 30, 2006 and 20,000 shares in the comparable period in 2005. The Company has accounted for these non-employee options in accordance with EITF 96-18 and, accordingly, recorded non-cash stock-based compensation expense of $62,000 for the nine months ended September 30, 2006 and $10,000 for the comparable period in 2005. Such amounts have been excluded from the table above which summarizes the affects of adopting FAS 123R.
Cash received from option exercises under all share-based payment arrangements for the three-month period ended September 30, 2006 was $184,000 and $460,000 for the comparable period in 2005. Cash received from option exercises and shares purchased under all share-based payment arrangements for the nine month period ended September 30, 2006 was $734,000 and $1.1 million for the comparable period in 2005. No tax benefit was recognized related to share-based
7
compensation expense since the Company has never reported taxable income and has established a full valuation allowance to offset all of the potential tax benefits associated with its deferred tax assets. In addition, no amounts of share-based compensation costs were capitalized for the periods presented.
Valuation assumptions
Option Plan and Directors’ Plan
The Company calculated the fair value of each option award on the date of grant using the Black-Scholes option pricing model. The following weighted-average assumptions were used for the periods indicated:
| Three Months Ended September 30, |
Nine months Ended September 30, |
|||||||||||
| 2006 | 2005 | 2006 | 2005 | |||||||||
| Risk-free interest rates |
4.8 | % | 4.0 | % | 4.7 | % | 3.8 | % | ||||
| Expected lives (in years) |
5.4 | 5.0 | 5.4 | 5.0 | ||||||||
| Dividend yield |
0 | % | 0 | % | 0 | % | 0 | % | ||||
| Expected volatility |
69 | % | 73 | % | 70 | % | 75 | % | ||||
The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for the expected life of the award. The Company’s computation of expected life was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. The estimated forfeiture rate applied to these amounts is derived from historical stock option forfeiture behavior. The Company has never paid cash dividends and does not currently intend to pay cash dividends, thus has assumed a 0% dividend yield. The Company’s computation of expected volatility is based on the historical volatility of the Company’s stock price. The Company’s stock price volatility and option lives involve management’s best estimates at that time, both of which impact the fair value of the option calculated under the Black-Scholes methodology, and ultimately the expense that will be recognized over the life of the option.
Stock Purchase Plan
The fair value of each option element of the Stock Purchase Plan is estimated on the date of grant using the Black-Scholes valuation model with the assumptions noted in the following table. The following range of assumptions was used in the three month ended and nine month ended periods indicated:
| Three Months Ended September 30, |
Nine months Ended September 30, | |||||||
| 2006 | 2005 | 2006 | 2005 | |||||
| Risk-free interest rates |
5.0% - 5.2% | 4.0% | 4.0% - 5.2% | 3.7% – 4.0% | ||||
| Expected lives (in years) |
0.5 – 2.0 | 0.5 – 2.0 | 0.5 – 2.0 | 0.5 – 2.0 | ||||
| Dividend yield |
0% | 0% | 0% | 0% | ||||
| Expected volatility |
70% | 75% | 70% - 74% | 74% -75% | ||||
The risk-free rate for periods within the contractual life of the purchasing period is based on the U.S. Treasury yield curve in effect at the beginning of the offering period. Expected term reflects the four, six month purchase periods within the Company’s two year offering period for the Stock Purchase Plan. The Company has never paid cash dividends and does not currently intend to pay cash dividends, thus has assumed a 0% dividend yield. Expected volatilities are based on historical volatility of the Company’s stock.
8
Stock-based payment award activity
The following table summarizes activity under the Company’s Option Plan and Directors’ Plan for the nine months ended September 30, 2006 (in thousands, except per share amounts and remaining contractual term in years):
| Shares | Weighted Average Exercise Price |
Weighted Average Remaining (in years) |
Aggregate Intrinsic Value | ||||||||
| Outstanding at December 31, 2005 |
4,821 | $ | 5.86 | ||||||||
| Granted |
2,480 | 4.80 | |||||||||
| Exercised |
(109 | ) | 3.16 | ||||||||
| Forfeited/expired/cancelled |
(391 | ) | 6.38 | ||||||||
| Outstanding at September 30, 2006 |
6,801 | $ | 5.49 | 7.65 | $ | 2,578 | |||||
| Options exercisable at September 30, 2006 |
3,225 | $ | 5.81 | 5.88 | $ | 1,750 | |||||
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for all options that were in-the-money at September 30, 2006. The aggregate intrinsic value of options exercised under the Company’s stock option plans was $161,000 during the nine months ended September 30, 2006 and $770,000 for the comparable period in 2005, determined as of the date of option exercise. As of September 30, 2006, there was approximately $6.8 million of total unrecognized compensation cost related to unvested share-based compensation arrangements, as adjusted for expected forfeitures, granted under the Company’s stock award plans. That cost is expected to be recognized over a weighted-average period of two years.
The weighted average grant-date fair value of options granted in the nine month period ended September 30, 2006 was $3.02 versus $3.55 for the comparable period in 2005. The weighted average grant-date fair value of the purchase rights existing under the Company’s Stock Purchase Plan during the first nine months of 2006 was $2.53 versus $2.52 for the comparable period in 2005.
Pro forma information for periods prior to the adoption of FAS 123R
Results for periods prior to January 1, 2006 have not been restated to reflect the effects of implementing FAS 123R. The following table illustrates the pro forma effect on net loss and net loss per share if a fair value method had been applied for each respective period (in thousands, except per share amounts):
| Three months ended September 30, 2005 |
Nine months ended September 30, 2005 |
|||||||
| Net loss attributable to common stockholders as reported |
$ | (6,171 | ) | $ | (22,084 | ) | ||
| Deduct: total stock compensation expense for employees determined under the fair value method |
(802 | ) | (3,224 | ) | ||||
| Pro forma net loss attributable to common stockholders |
$ | (6,973 | ) | $ | (25,308 | ) | ||
| Basic and diluted net loss per share |
||||||||
| As reported |
$ | (0.15 | ) | $ | (0.52 | ) | ||
| Pro forma |
$ | (0.16 | ) | $ | (0.60 | ) | ||
In the pro forma information required under FAS 123 for the periods prior to 2006, the Company accounted for forfeitures as they occurred.
4. Net loss per share
Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The Company has excluded all convertible preferred stock, warrants and options to purchase common stock from the calculation of diluted net loss per share as such securities are antidilutive for all periods presented.
9
The following table presents the weighted-average shares that have been excluded from the number of shares used to calculate basic and diluted net loss per share (in thousands):
| Three months ended September 30, |
Nine months ended September 30, | |||||||
| 2006 | 2005 | 2006 | 2005 | |||||
| Convertible preferred stock |
15,000 | 15,000 | 15,000 | 15,000 | ||||
| Warrants to purchase common stock |
2,050 | 2,050 | 2,050 | 2,050 | ||||
| Options to purchase common stock |
5,998 | 4,750 | 5,657 | 5,015 | ||||
| Total |
23,048 | 21,800 | 22,707 | 22,065 | ||||
5. Comprehensive loss
Comprehensive loss includes certain changes in equity that are excluded from net loss. Specifically, unrealized gains or losses in available for sale investments are included in accumulated other comprehensive loss. Comprehensive loss and its components were as follows (in thousands):
| Three months ended September 30, |
Nine months ended September 30, |
|||||||||||||||
| 2006 | 2005 | 2006 | 2005 | |||||||||||||
| Net loss |
$ | (8,649 | ) | $ | (6,171 | ) | $ | (25,995 | ) | $ | (22,084 | ) | ||||
| Unrealized gain (loss) on securities available for sale |
105 | (52 | ) | (133 | ) | (135 | ) | |||||||||
| Reclassification adjustment for realized losses included in net loss |
— | — | 289 | 1 | ||||||||||||
| Comprehensive loss |
$ | (8,544 | ) | $ | (6,223 | ) | $ | (25,839 | ) | $ | (22,218 | ) | ||||
6. Investments
Investments consist of available-for-sale securities as follows (in thousands):
| Amortized cost |
Gross Unrealized Gains |
Gross Unrealized Losses |
Fair Value | ||||||||||
| September 30, 2006 |
|||||||||||||
| U.S. corporate obligations |
$ | 49,473 | $ | 7 | $ | (11 | ) | $ | 49,469 | ||||
| U.S. government and agencies |
11,844 | 2 | (15 | ) | 11,831 | ||||||||
| Municipal bonds |
7,652 | 3 | (1 | ) | 7,654 | ||||||||
| Total |
$ | 68,969 | $ | 12 | $ | (27 | ) | $ | 68,954 | ||||
| Contractual Maturities |
|||||||||||||
| Due in one year or less |
$ | 59,470 | $ | 59,458 | |||||||||
| Due in one to three years |
9,499 | 9,496 | |||||||||||
| Total |
$ | 68,969 | $ | 68,954 | |||||||||
| Reported as: |
|||||||||||||
| Short-term investments |
$ | 58,964 | |||||||||||
| Long-term investments |
9,496 | ||||||||||||
| Restricted investments |
494 | ||||||||||||
| Total |
$ | 68,954 | |||||||||||
| December 31, 2005 |
|||||||||||||
| Mortgage-backed securities |
$ | 36,793 | $ | 85 | $ | (142 | ) | $ | 36,736 | ||||
| U.S. corporate obligations |
28,321 | — | (94 | ) | 28,227 | ||||||||
| U.S. government and agencies |
3,713 | — | (20 | ) | 3,693 | ||||||||
| Total |
$ | 68,827 | $ | 85 | $ | (256 | ) | $ | 68,656 | ||||
| Contractual Maturities |
|||||||||||||
| Due in one year or less |
$ | 32,034 | $ | 31,920 | |||||||||
| Mortgage-backed securities |
36,793 | 36,736 | |||||||||||
| Total |
$ | 68,827 | $ | 68,656 | |||||||||
| Reported as: |
|||||||||||||
| Short-term investments |
$ | 31,315 | |||||||||||
| Long-term investments |
36,736 | ||||||||||||
| Restricted investments |
605 | ||||||||||||
| Total |
$ | 68,656 | |||||||||||
10
During the second quarter of 2006, an investment decision was made to rebalance the portfolio away from mortgage-backed securities in an effort to improve the overall yield in the portfolio. As a result, certain available-for-sale securities were sold for total proceeds of $28,607,000 with an aggregate realized loss of $289,000. The aggregate realized losses on sales of available-for-sale securities for all other periods presented are not significant. The basis on which the cost of a security sold or the amount reclassified out of accumulated other comprehensive income into earnings was determined by the specific identification method.
The Company has determined that unrealized losses are not significant, temporary as to the extent of the decline, in both dollars and percentage of cost, and the Company has the ability and intent to hold investments until it recovers substantially all of the cost of the investments.
11
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations |
Forward-Looking Statements
The following discussion of our financial condition and results of operations contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as may, might, will, should, expect, plan, anticipate, project, believe, estimate, predict, potential, intend or continue, the negative of terms like these or other comparable terminology, and other words or terms of similar meaning in connection with any discussion of future operating or financial performance. These statements are only predictions. All forward-looking statements included in this document are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Any or all of our forward-looking statements in this document may turn out to be wrong. Actual events or results may differ materially. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties, many of which are beyond our control or our ability to predict. In evaluating these statements, you should specifically consider various factors, including the risks outlined under the caption “Risk Factors” set forth in Item 1A. of Part I of our Form 10-K for the fiscal year ended December 31, 2005, as updated by those risks appearing in Item 1A. of Part II of this Form 10-Q, as well as those contained from time to time in our other filings with the SEC. We caution investors that our business and financial performance are subject to substantial risks and uncertainties.
Overview
We are a biotechnology company developing monoclonal antibody-based therapies for the treatment of cancer and immunologic diseases. Our business strategy is focused on advancing our portfolio of product candidates in diseases with unmet medical need and significant market potential. We currently have three product candidates, SGN-40, SGN-33 and SGN-30, in ongoing clinical trials. In addition, we plan to initiate clinical testing of SGN-35 in the fourth quarter of 2006, and have two other lead preclinical product candidates, SGN-70 and SGN-75. Our pipeline of product candidates is based upon two technologies: genetically engineered monoclonal antibodies and monoclonal antibody-drug conjugates. These technologies enable us to develop monoclonal antibodies that can kill target cells on their own as well as to increase the potency of monoclonal antibodies by linking them to a cell-killing payload to form an antibody-drug conjugate (ADC).
In addition to our internal pipeline of product candidates, we have licensed our ADC technology to leading biotechnology and pharmaceutical companies, including Genentech, CuraGen, Bayer, MedImmune, PDL BioPharma and Progenics, through its wholly owned subsidiary PSMA Development Company. We also have internal research and in-licensing programs for novel antigens and new monoclonal antibodies to provide future opportunities for pipeline growth.
We do not currently have any commercial products for sale. All of our product candidates are in relatively early stages of development and significant further research and development, financial resources and personnel will be required to develop commercially viable products and obtain regulatory approvals. As of September 30, 2006, we had an accumulated deficit of approximately $169.6 million. Over the next several years, we expect to incur substantial expenses as we continue to invest in research, development and manufacturing and move towards commercialization of our product candidates. Our commitment of resources to research and the continued development and potential commercialization of our product candidates will require substantial additional funds and resources. Our operating expenses will likely increase as we invest in research or acquire additional technologies, as additional product candidates are selected for clinical development and as some of our earlier stage product candidates move into later stage clinical development. In addition, we may incur significant milestone payment obligations as our product candidates progress through clinical trials towards commercialization. Because a substantial portion of our revenues for the foreseeable future will depend on entering into new collaboration and license agreements and achieving development and clinical milestones under existing collaboration and license agreements, our results of operations may vary substantially from year to year and quarter to quarter. We believe that period to period comparisons of our operating results may not be meaningful and you should not rely on them as indicative of our future performance.
Financial summary
To date, we have generated revenues principally from our collaboration and license agreements. These revenues include upfront technology access fees, milestone payments and reimbursement for support and materials supplied to our collaborators. For the nine months ended September 30, 2006, revenues remained relatively constant at $7.4 million compared to the same period in 2005. Operating expenses increased 16% to $36.4 million compared to $31.5 million for the same period in 2005. Net loss for the nine month period ended September 30, 2006 was $26.0 million, or $0.54 per share, which includes the impact of FAS 123R stock-based compensation expense of $3.2 million or $0.07 per share. As of
12
September 30, 2006, we had approximately $96.4 million in cash, cash equivalents, short-term and long-term investments and total stockholders’ equity of $96.7 million, which amounts include approximately $43.1 million of net proceeds from our common stock financings during the second quarter of 2006.
Stock-based compensation
Effective January 1, 2006, we adopted FAS 123R, which requires the recognition of the fair value of stock-based compensation. Under the fair value recognition provisions for FAS 123R, stock-based compensation cost is estimated at the grant date based on the fair value of the awards expected to vest and recognized as expense ratably over the requisite service period of the award. We have used the Black-Scholes valuation model to estimate fair value of our stock-based awards, which requires various judgmental assumptions including estimating stock price volatility, forfeiture rates and expected life. Our computation of expected volatility, forfeiture rates and expected life is based on our historical experience. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense may differ significantly in the future from that recorded in the current period.
We adopted FAS 123R using the modified prospective method which requires the application of the accounting standard as of January 1, 2006. In accordance with the modified prospective method, the consolidated financial statements for prior periods have not been restated to reflect, and do not include, the impact of FAS 123R.
Results of Operations
Three months and nine months ended September 30, 2006 and 2005
Revenues.
| Three months ended September 30, |
Nine months ended September 30, |
|||||||||||||||||
| Revenues ($ in thousands) |
2006 | 2005 | % change | 2006 | 2005 | % change | ||||||||||||
| Earned portion of technology access fees and milestone payments |
$ | 1,721 | $ | 2,121 | -19 | % | $ | 6,021 | $ | 5,716 | 5 | % | ||||||
| Funded research and material supply fees |
720 | 511 | 41 | % | 1,401 | 1,722 | -19 | % | ||||||||||
| Total collaborations and license agreements |
$ | 2,441 | $ | 2,632 | -7 | % | $ | 7,422 | $ | 7,438 | 0 | % | ||||||
Total revenues decreased 7% to $2.4 million in the third quarter of 2006 and remained relatively constant at $7.4 million in the first nine months of 2006 from the comparable periods in 2005. 2006 revenues primarily reflect the earned portion of technology access fees and milestone payments, which decreased 19% to $1.7 million in the third quarter of 2006 and increased 5% to $6.0 million in the first nine months of 2006 from the comparable periods in 2005. These revenues represent upfront technology access fees or milestones received during the course of our ADC collaborations with Genentech, CuraGen, Bayer, MedImmune, PDL BioPharma, PSMA Development Company and UCB Celltech. Upfront technology access fees received are generally deferred and recognized ratably over each collaborative research period. Payments received from our collaborators for the achievement of substantive milestones are generally recognized when the milestone is achieved, and payments for milestones which are not the result of the achievement of a substantive milestone are recognized ratably over the research period. In the second quarter of 2006, we earned a milestone under our ADC collaboration with CuraGen upon the initiation of clinical testing by CuraGen of its lead ADC product candidate utilizing our technology. Funded research and material supply fees increased 41% to $720,000 in the third quarter of 2006 from the comparable period in 2005 due to both increased levels of funded research support and increased material supply delivered during the quarter. Funded research and material supply fees decreased 19% to $1.4 million in the first nine months of 2006 from the comparable period in 2005 due to lower levels of funded research support with existing collaborators, which vary over the collaborative research period. The decrease also reflects the expiration of the ADC research collaboration with UCB Celltech.
We continue to expect that our revenues in 2006 will increase modestly over 2005 levels, driven primarily by recognition of deferred payments previously received under our ADC collaborations and to a lesser degree by payments received for materials, support that we provide to our collaborators and milestone achieved. We expect that future revenues will vary from quarter to quarter depending on the level of support we provide our partners and the timing of milestones achieved and may decrease if we do not enter into additional collaboration agreements.
13
Research and development.
Research and development expenses increased 26% to $9.8 million in the third quarter of 2006 and increased 11% to $29.1 million in the first nine months of 2006 from the comparable periods in 2005. Our research and development expenses are summarized as follows:
| Three months ended September 30, |
Nine months ended September 30, |
|||||||||||||||||
| Research and Development ($ in thousands) |
2006 | 2005 | % change | 2006 | 2005 | % change | ||||||||||||
| Research |
$ | 3,102 | $ | 2,991 | 4 | % | $ | 9,529 | $ | 9,102 | 5 | % | ||||||
| Development and contract manufacturing |
4,020 | 3,655 | 10 | % | 11,713 | 12,301 | -5 | % | ||||||||||
| Clinical |
1,812 | 1,160 | 56 | % | 5,754 | 4,733 | 22 | % | ||||||||||
| Stock compensation expense |
863 | — | N/A | 2,059 | 10 | 20,490 | % | |||||||||||
| Total |
$ | 9,797 | $ | 7,806 | 26 | % | $ | 29,055 | $ | 26,146 | 11 | % | ||||||
Research expenses include, among other things, personnel, occupancy and laboratory expenses associated with the discovery and identification of new monoclonal antibodies and the development of novel classes of stable linkers and potent cell-killing drugs. Research expenses also include research activities associated with our product candidates, such as preclinical translation biology, in vitro and in vivo studies. Research expenses increased 4% to $3.1 million in the third quarter of 2006 versus the comparable period in 2005 primarily due to increased compensation expenses and lab supply expenses. Research expenses in the first nine months of 2006 increased 5% to $9.5 million from the comparable period in 2005 primarily due to increased compensation expenses, recruiting and relocation expenses.
Development and contract manufacturing expenses include personnel, occupancy expenses and external contract manufacturing costs for the scale up and manufacturing of drug product for use in our clinical trials, including IND-enabling pharmacology and toxicology studies. Development and contract manufacturing expenses also include quality control and assurance activities, including storage and shipment services of our drug product candidates. Development and contract manufacturing costs increased 10% to $4.0 million in the third quarter of 2006 from the comparable period in 2005 due to increased personnel expenses and lab supplies related to higher staffing levels. This increase is net of lower contract manufacturing expenses in the third quarter of 2006 attributable to decreased manufacturing costs of SGN-40 and SGN-35 and higher costs for SGN-70 and SGN-33. For the first nine months of 2006, development and contract manufacturing costs decreased 5% to $11.7 million from the comparable period in 2005 primarily due to the timing of manufacturing campaigns. Manufacturing costs decreased by $3.4 million for SGN-40 and $800,000 for SGN-35 in the first nine months of 2006 from the comparable period in 2005, reflecting the substantial completion of related activities for those programs during 2005. SGN-70 contract manufacturing costs increased $2.0 million in the first nine months of 2006 from the comparable period in 2005. The decrease in development and contract manufacturing expenses for the first nine months of 2006 is net of higher personnel expenses, lab supplies associated with higher staffing levels and depreciation expenses.
Clinical expenses include personnel expenses, travel, occupancy costs and external clinical trial costs including principal investigator fees, clinical site expenses, clinical research organization charges and regulatory activities associated with conducting human clinical trials. Clinical costs increased 56% to $1.8 million in the third quarter of 2006 and increased 22% to $5.8 million in the first nine months of 2006 from the comparable periods in 2005 primarily due to higher third party costs for our SGN-40 phase I trials, SGN-33 phase I trial and SGN-30 phase II trials during 2006.
Stock compensation expenses reflect the non-cash charge relating to the adoption of FAS 123R on January 1, 2006, which requires us to measure the fair value of all employee share-based payments and recognize that value as an operating expense. With the adoption of FAS 123R, we expect an increase in our non-cash operating expenses for employee stock-based compensation in the remaining period of 2006 when compared to 2005.
14
We utilize our employee and infrastructure resources across multiple projects, including our discovery and research programs directed towards identifying monoclonal antibodies and new classes of stable linkers and cell-killing drugs. Many of our costs are not directly attributable to a specific project and we have not historically allocated our infrastructure costs or accounted for internal research and development costs on a project-by-project basis. As a result, we do not report actual total costs incurred for each of our clinical and preclinical projects on a project-by-project basis. We do, however, separately account for significant third-party costs of development programs identified as product candidates for further preclinical and clinical development. The following table shows expenses incurred for preclinical study support, contract manufacturing for clinical supplies and clinical trial services provided by third parties as well as milestone payments for in-licensed technology for each of our product candidates and the remaining unallocated costs for such periods:
| Three months ended September 30, | Nine months ended September 30, | Five years ended September 30, 2006 | |||||||||||||
| Product Candidates ($ in thousands) |
2006 | 2005 | 2006 | 2005 | |||||||||||
| SGN-40 |
$ | 359 | $ | 1,289 | $ | 1,402 | $ | 3,944 | $ | 6,963 | |||||
| SGN-33 |
322 | 44 | 604 | 52 | 1,346 | ||||||||||
| SGN-35 |
143 | 450 | 1,290 | 2,047 | 8,203 | ||||||||||
| SGN-30 |
341 | 431 | 1,338 | 1,384 | 19,700 | ||||||||||
| SGN-70 |
699 | 81 | 2,043 | 81 | 2,369 | ||||||||||
| Total third party costs |
1,864 | 2,295 | 6,677 | 7,508 | 38,581 | ||||||||||
| Unallocated costs and overhead |
7,070 | 5,511 | 20,319 | 18,628 | 104,712 | ||||||||||
| Stock compensation expense |
863 | — | 2,059 | 10 | 4,033 | ||||||||||
| Total research and development |
$ | 9,797 | $ | 7,806 | $ | 29,055 | $ | 26,146 | $ | 147,326 | |||||
SGN-40 costs primarily reflect third party clinical costs in 2006 and contract manufacturing costs incurred at Abbott Laboratories in 2005. We expect third party costs associated with clinical trials of SGN-40 to increase as we continue to enroll patients and expand our SGN-40 phase I clinical trials and initiate phase II trials. However, we expect contract manufacturing costs for SGN-40 in 2006 to be lower than 2005 due to the completion of our manufacturing campaign for clinical-grade materials at Abbott Laboratories in 2005. Costs attributable to SGN-33 in the third quarter and first nine months of 2006 include clinical trial costs for our phase I clinical trial and the start of our manufacturing campaign at Laureate Pharma. Our third party costs for SGN-35 in the third quarter and the first nine months of 2006 and 2005 are primarily attributable to contract manufacturing and preclinical studies necessary to initiate a planned clinical trial in the fourth quarter of 2006. We expect third party costs for SGN-35 to increase as we initiate this phase I clinical trial. SGN-30 third party costs in the third quarter and the first nine months of 2006 and 2005 are primarily attributable to patient enrollment in our phase II clinical trials in the United States and Europe. We expect third party costs for SGN-30 during 2006 to remain relatively consistent with the amounts incurred in 2005 as we complete our phase II clinical trials and to decrease thereafter. We have initiated clinical trials of SGN-30 in cooperation with the National Cancer Institute, the costs of which will be incurred by the institute and not reflected in our financial results. Our third party costs for SGN-70 in the third quarter of 2006 are primarily attributable to our ongoing manufacturing campaign for clinical-grade material at Laureate Pharma, which we expect to increase during the fourth quarter of 2006. We expect that our total research and development expenses in 2006 will increase over 2005 levels, primarily driven by manufacturing activities for SGN-33 and SGN-70 with Laureate Pharma, increased clinical costs for SGN-40, SGN-33 and SGN-35, and the adoption of FAS 123R which has resulted in the expensing of stock option grants to employees.
Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. In order to advance our product candidates toward eventual commercialization, the product candidates are tested in numerous preclinical safety, toxicology and efficacy studies. We then conduct clinical trials for those product candidates that may take several years or more to complete. The length of time varies substantially based upon the type, complexity, novelty and intended use of a product candidate. The cost of clinical trials may vary significantly over the life of a project as a result of a variety of factors, including:
| • | The number of patients who participate in the trials; |
| • | The length of time required to enroll trial participants; |
| • | The number of sites included in the trials; |
| • | The costs of producing supplies of the product candidates needed for clinical trials and regulatory submissions; |
| • | The safety and efficacy profile of the product candidate; |
| • | The use of clinical research organizations to assist with the management of the trials; and |
| • | The costs and timing of, and the ability to secure, regulatory approvals. |
Furthermore, our strategy may include entering into collaborations with third parties to participate in the development and commercialization of some of our product candidates. In these situations, the preclinical development or clinical trial process for a product candidate and the estimated completion date may largely be under the control of that third party and not under our control. We cannot forecast with any degree of certainty which of our product candidates will be subject to future collaborations or how such arrangements would affect our development plans or capital requirements.
We anticipate that our research, development, contract manufacturing and clinical expenses will continue to grow in the foreseeable future as we expand our discovery and preclinical activities, as new product candidates enter clinical trials and as we advance our product candidates already in clinical trials to new clinical sites in North America and Europe. These expenses will fluctuate based upon many factors including the degree of collaborative activities, timing of manufacturing campaigns, numbers of patients enrolled in our clinical trials and the outcome of each clinical trial event.
15
The risks and uncertainties associated with our research and development projects are discussed more fully in the sections entitled “Risk Factors” that appear in our periodic reports filed with the SEC. As a result of the uncertainties discussed above, we are unable to determine with any degree of certainty the duration and completion costs of our research and development projects, anticipated completion dates or when and to what extent we will receive cash inflows from the commercialization and sale of a product candidate.
General and administrative.
| Three months ended September 30, |
Nine months ended September 30, |
|||||||||||||||||
| General and administrative($ in thousands) |
2006 | 2005 | % change | 2006 | 2005 | % change | ||||||||||||
| General and administrative |
$ | 2,191 | $ | 1,664 | 32 | % | $ | 6,143 | $ | 5,366 | 14 | % | ||||||
| Stock compensation expense |
428 | — | n/a | 1,185 | — | n/a | ||||||||||||
| Total general and administrative expense |
$ | 2,619 | $ | 1,664 | 57 | % | $ | 7,328 | $ | 5,366 | 37 | % | ||||||
General and administrative expenses increased 57% to $2.6 million in the third quarter of 2006 and increased 37% to $7.3 million in the first nine months of 2006 from the comparable periods in 2005. General and administrative expenses, excluding stock compensation expense, increased 32% in the third quarter of 2006 and 14% in the first nine months of 2006 from the comparable periods in 2005 primarily due to higher compensation, consulting and professional services expenses. Stock compensation expenses reflect non-cash charges relating to the adoption of FAS 123R on January 1, 2006, which requires us to measure the fair value of all employee share-based payments and recognize that value as an operating expense. With the adoption of FAS 123R, we expect an increase in our non-cash operating expenses for employee share-based compensation in the remaining period of 2006 as compared to 2005. We also anticipate that general and administrative expenses will increase in 2006 as a result of costs related to adding personnel in support of our operations.
Investment income, net.
Investment income increased 99% to $1.3 million in the third quarter of 2006 and increased 49% to $3.0 million in the first nine months of 2006 from the comparable periods in 2005 due primarily to higher cash and investment balances as a result of our common stock financings in the second quarter of 2006, as well as an increase in the average yield of invested funds. Investment income for the first nine months of 2006 reflects realized losses of $289,000 following an investment decision made during the second quarter of 2006 to rebalance the portfolio away from mortgage-backed securities in an effort to improve the overall yield of the portfolio.
Liquidity and Capital Resources.
| Liquidity and capital resources ($ in thousands) |
September 30, 2006 |
December 31, 2005 |
||||||
| Cash, cash equivalents and investments |
$ | 96,371 | $ | 79,207 | ||||
| Working capital |
$ | 80,054 | $ | 33,048 | ||||
| Nine months ended September 30, |
||||||||
| 2006 | 2005 | |||||||
| Cash provided by (used in): |
||||||||
| Operating activities |
$ | (25,491 | ) | $ | (18,336 | ) | ||
| Investing activities |
$ | (1,634 | ) | $ | 18,474 | |||
| Financing activities |
$ | 43,880 | $ | 1,123 | ||||
| Capital expenditures (included in Investing activities) |
$ | (1,158 | ) | $ | (1,190 | ) | ||
We have financed the substantial majority of our operations through the public and private sale of equity securities, which is supplemented by funding received from our collaboration and license agreements. To a lesser degree, we have also financed our operations through interest earned on cash, cash equivalents and investments. These financing sources have historically allowed us to maintain adequate levels of cash and investments.
16
Our combined cash, cash equivalents and investment securities increased to $96.4 million at September 30, 2006, compared to $79.2 million at December 31, 2005. The increase in 2006 was primarily the result of net proceeds of $43.1 million from our common stock financings that closed during the second quarter, offset by $25.5 million used to finance our operations. Our working capital was $80.1 million at September 30, 2006, compared to $33.0 million at December 31, 2005. The increase in working capital during 2006 reflects the proceeds from our common stock financings as well as changes in the composition of our investment portfolio to improve overall returns. We have structured our investment portfolio so that scheduled maturities of investment securities can be used to fund our working capital needs. Our cash, cash equivalents and investments are held in a variety of interest-bearing instruments, consisting primarily of U.S. government and agency securities, high-grade U.S. corporate bonds, taxable municipal bonds, commercial paper and money market accounts.
Capital expenditures remained relatively constant at $1.2 million during the first nine months of 2006 from the comparable period in 2005 and consisted primarily of lab equipment and computers and related information systems in support of our research and development activities and employee growth. We expect that our capital expenditures for the year 2006 to exceed 2005 amounts reflecting higher capital purchases and facilities improvements.
At our currently planned spending rate, we believe our remaining financial resources in addition to the expected fees and milestone payments earned under new and existing collaboration and license agreements will be sufficient to fund our operations until late 2008. However, changes in our spending rate may occur that would consume available capital resources sooner, such as increased manufacturing and clinical trial expenses preceding commercialization of a product candidate. We may seek additional funding through some or all of the following methods: corporate collaborations, licensing arrangements, or public or private equity financings. We do not know whether additional capital will be available when needed, or that, if available, we will obtain financing on terms favorable to our stockholders or us. If we are unable to raise additional funds should we need them, we may be required to delay, reduce or eliminate some of our development programs, which may adversely affect our business and operations.
We expect to incur substantial costs as we continue to develop and commercialize our product candidates. We anticipate that our rate of overall spending will accelerate as a result of the increased expenses associated with adding personnel, clinical trials, regulatory filings, manufacturing, and research and development activities. However, we may experience fluctuations in incurring these costs from quarter to quarter based on the timing of manufacturing campaigns, accrual of patients to clinical trials and collaborative activities. Certain external factors may influence our cash spending including the cost of filing and enforcing patent claims and other intellectual property rights, competing technological and market developments and the progress of our collaborators.
Some of our manufacturing, license and collaboration agreements provide for the payment of periodic maintenance fees over specified time periods, as well as payments by us upon the achievement of development and regulatory milestones and the payment of royalties based on commercial product sales. We do not expect to pay any royalties on net sales of products under any of these agreements for at least the next several years. The amounts set forth below could be substantially higher if we are required to make milestone payments or if we receive regulatory approvals or achieve commercial sales and are required to pay royalties earlier than anticipated.
The following are our future minimum contractual commitments for the periods subsequent to September 30, 2006 (in thousands):
| Total | Remainder of 2006 |
2007 | 2008 | 2009 | 2010 | Thereafter | |||||||||||||||
| Operating leases |
$ | 10,478 | $ | 544 | $ | 2,197 | $ | 2,231 | $ | 2,253 | $ | 2,291 | $ | 962 | |||||||
| Manufacturing, license and collaboration agreements |
6,350 | 3,715 | 1,885 | 335 | 205 | 210 | — | ||||||||||||||
| Total |
$ | 16,828 | $ | 4,259 | $ | 4,082 | $ | 2,566 | $ | 2,458 | $ | 2,501 | $ | 962 | |||||||
The minimum payments under manufacturing, license and collaboration agreements in 2006 primarily represent contractual obligations related to manufacturing campaigns to perform scale-up and cGMP manufacturing for monoclonal antibody and ADC product candidates for use in our clinical trials, including our contract manufacturing agreement with Laureate Pharma. The above table excludes royalties and up to approximately $14.0 million in potential future milestone payments to third parties under manufacturing, license and collaboration agreements for our current development programs, which generally become due and payable only upon achievement of certain developmental, regulatory and/or commercial milestones. Because the achievement of these milestones is neither probable nor reasonably estimable, such contingent payments have not been included in the above table.
17
Under the terms of our office and laboratory lease, we have collateralized the lease with approximately $494,000 of our investments and the majority of our property and equipment. These investment securities are restricted as to withdrawal and are managed by a third party. In the event that we fail to meet specific thresholds of market capitalization, stockholders’ equity or cash and investment balances, we are obligated to increase our restricted investment balance to approximately $3.4 million. At September 30, 2006, we were in compliance with these thresholds.
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk |
In accordance with our investment policy, we do not have any derivative financial instruments in our investment portfolio. We invest in high quality interest-bearing instruments, consisting of U.S. government and agency securities, high-grade U.S. corporate bonds, taxable municipal bonds, adjustable mortgage-backed securities, commercial paper and money market accounts. Such securities are subject to interest rate risk and will rise and fall in value if market interest rates change; however, we do not expect any material loss from such interest rate changes.
| Item 4. | Controls and Procedures |
(a) Evaluation of disclosure controls and procedures. The Chief Executive Officer and the Chief Financial Officer have reviewed the Company’s disclosure controls and procedures prior to the filing of this quarterly report. Based on that review, they have concluded that, as of the end of the period covered by this quarterly report, these disclosure controls and procedures were, in design and operation, effective to assure that the required information has been properly recorded, processed, summarized and reported to those responsible in order that it may be included in this quarterly report.
(b) Changes in internal control over financial reporting. There have not been any changes in the Company’s internal control over financial reporting during the quarter ended September 30, 2006 which have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Part II. Other Information
| Item 1A. | Risk Factors |
Certain factors may have a material adverse effect on our business, financial condition and results of operations and you should carefully consider them. It is not possible to predict or identify all such factors, and additional risks and uncertainties not currently known to us or that we currently deem immaterial also may adversely affect our business, financial condition and results of operations. For discussion of some of our potential risks or uncertainties, refer to Part I, Item 1A., Risk Factors, included in our Form 10-K for the fiscal year ended December 31, 2005 and our Form 10-Q for the fiscal quarters ended March 31, 2006 and June 30, 2006, all as filed with the SEC. We have not had any material changes to the risk factors described in such filings during the quarter ended September 30, 2006.
18
| Item 6. | Exhibits |
| Number | Description | |
| 3.1(1) | Amended and Restated Certificate of Incorporation of Seattle Genetics, Inc. | |
| 3.2(2) | Certificate of Designations of Series A Convertible Preferred Stock of Seattle Genetics, Inc. | |
| 3.3(4) | Amended and Restated Bylaws of Seattle Genetics, Inc. | |
| 4.1(1) | Specimen Stock Certificate. | |
| 4.2(3) | Form of Common Stock Warrant. | |
| 4.3(3) | Investor Rights Agreement dated July 8, 2003 among Seattle Genetics, Inc. and certain of its stockholders. | |
| 31.1 | Certification of Chief Executive Officer pursuant to Rule 13a-14(a). | |
| 31.2 | Certification of Chief Financial Officer pursuant to Rule 13a-14(a). | |
| 32.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350. | |
| 32.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350. | |
| (1) | Previously filed as an exhibit to Registrant’s registration statement on Form S-1, File No. 333-50266, originally filed with the Commission on November 20, 2000, as subsequently amended, and incorporated herein by reference. |
| (2) | Previously filed as an exhibit to the Registrant’s current report on Form 8-K filed with the Commission on June 5, 2003. |
| (3) | Previously filed as an exhibit to the Registrant’s current report on Form 8-K filed with the Commission on May 15, 2003. |
| (4) | Previously filed as an exhibit to the Registrant’s quarterly report on Form 10-Q for the quarter ended June 30, 2003 and incorporated herein by reference. |
19
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SEATTLE GENETICS, INC. | ||
| By: | /s/ Todd E. Simpson | |
| Todd E. Simpson | ||
| Chief Financial Officer | ||
Date: November 7, 2006
20
| Number | Description | |
| 3.1(1) | Amended and Restated Certificate of Incorporation of Seattle Genetics, Inc. | |
| 3.2(2) | Certificate of Designations of Series A Convertible Preferred Stock of Seattle Genetics, Inc. | |
| 3.3(4) | Amended and Restated Bylaws of Seattle Genetics, Inc. | |
| 4.1(1) | Specimen Stock Certificate. | |
| 4.2(3) | Form of Common Stock Warrant. | |
| 4.3(3) | Investor Rights Agreement dated July 8, 2003 among Seattle Genetics, Inc. and certain of its stockholders. | |
| 31.1 | Certification of Chief Executive Officer pursuant to Rule 13a-14(a). | |
| 31.2 | Certification of Chief Financial Officer pursuant to Rule 13a-14(a). | |
| 32.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350. | |
| 32.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350. | |
| (1) | Previously filed as an exhibit to Registrant’s registration statement on Form S-1, File No. 333-50266, originally filed with the Commission on November 20, 2000, as subsequently amended, and incorporated herein by reference. |
| (2) | Previously filed as an exhibit to the Registrant’s current report on Form 8-K filed with the Commission on June 5, 2003. |
| (3) | Previously filed as an exhibit to the Registrant’s current report on Form 8-K filed with the Commission on May 15, 2003. |
| (4) | Previously filed as an exhibit to the Registrant’s quarterly report on Form 10-Q for the quarter ended June 30, 2003 and incorporated herein by reference. |
21